Abstract
Arylamine N-acetyltransferases (NATs) are a family of enzymes found in eukaryotes and prokaryotes. While the precise endogenous function of NAT remains unknown for most organisms, recent evidence has shown that the expression of human NAT1 is up-regulated in estrogen receptor positive breast cancer. Additionally, NAT in mycobacteria is required for mycobacterial cell wall biosynthesis and survival of the organisms within macrophage. It is therefore important to develop small molecule inhibitors of NATs as molecular tools to study the function of NATs in various organisms. Such inhibitors may also prove useful in future drug design, for example in the development of anti tubercular agents. We describe a high throughput screen of a proprietary library of 5016 drug-like compounds against three prokaryotic NAT enzymes and two eukaryotic NAT enzymes.
Keywords: Arylamine N-acetyltransferases, NATs, high throughput screening, drug discovery, Amycolatopsis mediterranei, Mycobacterium bovis, Mycobacterium tuberculosis, TBNAT, Salmonella, STNAT, Mycobacterium smegmatis, MSNAT, Pseudomonas aeruginosa, PANAT, Mesorhizobium loti, MLNAT, Mycobacterium marinum, MMNAT, Tecan Sunrise plate reader, basic median-polish mode, Ellman's reagent, pABA, NMR
Combinatorial Chemistry & High Throughput Screening
Title: Novel Small-Molecule Inhibitors of Arylamine N-Acetyltransferases: Drug Discovery by High Throughput Screening
Volume: 14 Issue: 2
Author(s): Isaac M. Westwood, Akane Kawamura, Angela J. Russell, James Sandy, Stephen G. Davies and Edith Sim
Affiliation:
Keywords: Arylamine N-acetyltransferases, NATs, high throughput screening, drug discovery, Amycolatopsis mediterranei, Mycobacterium bovis, Mycobacterium tuberculosis, TBNAT, Salmonella, STNAT, Mycobacterium smegmatis, MSNAT, Pseudomonas aeruginosa, PANAT, Mesorhizobium loti, MLNAT, Mycobacterium marinum, MMNAT, Tecan Sunrise plate reader, basic median-polish mode, Ellman's reagent, pABA, NMR
Abstract: Arylamine N-acetyltransferases (NATs) are a family of enzymes found in eukaryotes and prokaryotes. While the precise endogenous function of NAT remains unknown for most organisms, recent evidence has shown that the expression of human NAT1 is up-regulated in estrogen receptor positive breast cancer. Additionally, NAT in mycobacteria is required for mycobacterial cell wall biosynthesis and survival of the organisms within macrophage. It is therefore important to develop small molecule inhibitors of NATs as molecular tools to study the function of NATs in various organisms. Such inhibitors may also prove useful in future drug design, for example in the development of anti tubercular agents. We describe a high throughput screen of a proprietary library of 5016 drug-like compounds against three prokaryotic NAT enzymes and two eukaryotic NAT enzymes.
Export Options
About this article
Cite this article as:
M. Westwood Isaac, Kawamura Akane, J. Russell Angela, Sandy James, G. Davies Stephen and Sim Edith, Novel Small-Molecule Inhibitors of Arylamine N-Acetyltransferases: Drug Discovery by High Throughput Screening, Combinatorial Chemistry & High Throughput Screening 2011; 14 (2) . https://dx.doi.org/10.2174/138620711794474051
DOI https://dx.doi.org/10.2174/138620711794474051 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Signal Transduction of Radiation and/or Hyperthermic Cancer Therapies
Current Signal Transduction Therapy Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology Regulation of Gene Expression by Progesterone in Cancer Cells: Effects on Cyclin D1, EGFR and VEGF
Mini-Reviews in Medicinal Chemistry VEGF Promotes Glycolysis in Pancreatic Cancer via HIF1α Up-Regulation
Current Molecular Medicine Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design CAM Use in Pediatric Oncology
Current Pediatric Reviews Neuroimmune Activation in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges
Current Drug Targets Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin
Anti-Cancer Agents in Medicinal Chemistry Gene Delivery for Cancer Therapy
Current Drug Delivery Current Concepts on the Genetics and Pharmacogenetics of Inflammatory Bowel Disease: Do they Help in Clinical Management?
Current Genomics Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Antimalarial Activity of an N-Alkyl Diamine
Letters in Drug Design & Discovery Hesperidin Potentiates Ghrelin Signaling
Recent Patents on Food, Nutrition & Agriculture The Application of Chitosan and Its Derivatives as Nanosized Carriers for the Delivery of Chemical Drugs and Genes or Proteins
Current Drug Targets Healthy Properties of Garlic
Current Nutrition & Food Science Equol is Neuroprotective During Focal Cerebral Ischemia and Reperfusion that Involves p-Src and gp91<sup>phox</sup>
Current Neurovascular Research Other Future Targeting Therapy Beyond TNF-α Inhibitor in Patients with Spondyloarthropathy
Current Rheumatology Reviews Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets